Ann: Quarterly Business Review & App. 4C, page-2

Cost reduction program continues with transitional activities well underway to transform Oventus Medical Ltd (OVN) from being a predominantly R&D focussed company to a sales oriented company; spend reduction expected to kick in during calendar Q4 2018. With the product development undertaken and supporting clinical trial data being generated, in combination with access to existing reimbursement codes and a clear regulatory pathway, Oventus is now emerging as an airway management company. According to Oventus, with strong interest in its 'Sleep Treatment Platform' and continued adoption across dental and sleep channels, it should start to see increasing revenues in future quarters

http://crweworld.com/australia/tren...td-ovnax-quarterly-business-review-q4-fy2018-